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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of corticosteroids, with and without antibiotics, for AOM in children.
B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is a common complication of an acute
respiratory infection (ARI); it mostly affects children aged six to
12 months (Lieberthal 2013; SACHCN 2014).
A 2015 update of a clinical practice guideline on the diagnosis
and management of AOM states that “Clinicians should diagnose
AOM in children who present with moderate-to-severe bulging
of the tympanic membrane or new onset of otorrhoea not due
to acute otitis externa; and may diagnose AOM in children who
present with mild bulging of the tympanic membrane and re-
cent (< 48 hours) onset of ear pain (holding, tugging, rubbing
of the ear in a nonverbal child) or intense erythema of the tym-
panic membrane” (Pichichero 2015). The 2014 New SouthWales
Health (Australia) clinical practice guideline defines AOM as an
“acute onset of middle ear inflammation characterised by 1) dis-
tinct otalgia (ear pain) that interferes with normal activity or sleep;
2) bulging tympanic membrane and erythema; and 3) possible
perforation and otorrhoea (ear discharge)” (NSW Health 2014).
In young children aged from six months to three years the overall
incidence of AOM as a complication of ARIs (mostly caused by
rhinovirus and adenovirus) was shown to be 37% in a prospective,
longitudinal cohort study (Chonmaitree 2008). Fifty per cent of
acute symptoms (pain and systemic symptoms) resolve within 24
hours and 80% within 72 hours. Children aged up to two years
often experience more severe and protracted illness (Chonmaitree
2008). Studies from Europe and the US have reported that 62%
of children aged up to 12 months, and 83% of children aged
between one and three years, experience at least one episode of
AOM. Among these children, between 10% and 30% experience
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recurrent AOM, and 2% to 25% experience persistent middle
ear effusion for three months, many requiring ventilation tube
(grommet) insertion (Gribben 2012; Kitamura 2015).
The prevalences of AOMare slightly varied across Asian countries.
In Korea, a 1991 national survey reported a point prevalence of
0.08% for AOM in children aged up to 15 years (Lee 2012); in
Malaysia, 9% of children aged from three months to 12 years
experienced AOM over the previous three years (Tikaram 2012).
A 2005 study in Taiwan found that 13.2% of children aged up to
seven years had experienced AOM (Ting 2012). In East Jakarta,
Indonesia, the point prevalence of AOM in children aged from
two to five years was 5.4% (Umar 2013).
As the risk of AOM increases in the indigenous population, a
cluster survey in Indigenous versus non-Indigenous children in
Australia found that severe otitis media was more prevalent in
Indigenous children (7.9%) compared tonon-Indigenous children
(1.7%) (Gunasekera 2007).
Pain is one of the most common and distressing symptoms of
AOM.Many clinical practice guidelines have recommended anal-
gesic (e.g. paracetamol, ibuprofen) as an initial treatment option
for pain management in AOM (Lieberthal 2013; NSW Health
2014; SACHCN 2014). A study on the use of ibuprofen versus
acetaminophen and placebo for the symptoms of AOM in chil-
dren showed no significant differences between treatment groups
in the improvement of tympanic membrane inflammation, rec-
tal temperature, appetite, sleep and playing activity 48 hours af-
ter treatment (Bertin 1996). However, there was a modest bene-
fit of ibuprofen over placebo in reducing pain. There was no sig-
nificant difference between acetaminophen and placebo. Topical
analgesics have limited evidence of efficacy in reducing ear pain
(Foxlee 2011).
Antibiotics are also commonly prescribed in the treatment for
AOM. Antibiotics have a modest effect in reducing pain at two to
three days, with a number needed to treat to benefit (NNTB) of
20 children (Venekamp 2015). Despite using antibiotics, 11% to
19% of children with AOM experience persistent symptoms for
more than six days (Lieberthal 2013). Ear effusions may persist in
30% to 60% of children for up to one month, and in 15% to 25%
of children for up to three months (Chonmaitree 2003). Almost
one-third of these children do not have bacterial growth from
their MEE. One-third of affected children experience recurrence
within a month (Chonmaitree 2003). Nevertheless, the clinical
practice guideline of the American Academy of Pediatrics strongly
recommends antibiotics for children aged six months and older
with bilateral or unilateral AOM and severe signs or symptoms.
Antibiotics are also recommended for children younger than two
years with bilateral AOM without severe signs or symptoms (
Lieberthal 2013).
An alternative strategy for the management of AOM in children
is close observation through follow-up, based on joint decision-
making with the parent or caregiver. However, close observation
requires accessible follow-up and continuity of care (Lieberthal
2013; Pichichero 2015).Observation alonemaynot be suitable for
high-risk or vulnerable populations such as Indigenous children
in remote settings or those with complications such as cleft palate,
Down syndrome or immunodeficiency syndromes (Morris 2009;
NSW Health 2014).
Other treatments, such as decongestants or antihistamines, are not
recommended for children due to the risk of adverse events and
the lack of benefit. There is limited evidence on the use of de-
congestant/antihistamine combinations for AOM in children: a
Cochrane review found a small statistical benefit from the combi-
nation medication, but the clinical significance was minimal and
the contributing studies may have been biased (Coleman 2008).
However, the 2015 Japanese clinical practice guideline on the di-
agnosis and management of AOM in children recommended use
of complementary nasal treatment for children with AOM asso-
ciated with nasal disease (Kitamura 2015). A study on the use of
intranasal steroid spray (triamcinolone acetonide) for otitis me-
dia with effusion and negative middle ear pressure showed there
was no statistically significant difference in the normalization of
the tympanometric findings between intranasal steroid group and
placebo in six weeks (Gluth 2011). A Cochrane review on the use
of topical intranasal steroids for otitis media effusion in children
also found no evidence of benefit in terms of symptoms (including
ear symptoms that are crucial in the management of AOM) either
at short- or longer-term follow-up (Simpson 2011).
Description of the intervention
Corticosteroids are natural steroid hormones produced by the
adrenal cortex, which can be synthetically manufactured. They
have an important anti-inflammatory role (Gupta 2008), and they
have been used for a wide range of both acute and chronic inflam-
matory illnesses in adults and children (Coutinho 2011).
There are concerns about the possible risks associated with cor-
ticosteroid use, such as increased appetite, weight gain, fluid re-
tention, gastritis, headache, mood swings, increased blood glu-
cose and Addisonian crisis from abrupt stopping of the corticos-
teroid, all of which can occur with protracted use. However, in
general, short-term use (one week or less) does not cause these
harms or require dose-tapering (Deshmukh 2007). A randomised
controlled trial (RCT) of corticosteroids for AOM found no cor-
relation between the emergence of viral infection and corticos-
teroid use (Chonmaitree 2003). A Cochrane review on the use of
systematic corticosteroids for acute sinusitis found no serious side
effects (Venekamp 2014).
How the intervention might work
Persistent middle ear effusion (MEE) after resolution of AOM is
a concern. MEE has been found in 60% to 70% of children two
weeks after successful antibiotic treatment of AOM. Presentation
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decreases to 10% to 25% at three months, but in 5% to 10%
of cases MEE is present one year later (Lee 2012; Lieberthal
2013; Lighthall 2015; Mahadevan 2012; Rosenfeld 2001). One
cause of MEE is dysfunction of the Eustachian tube due to the
inflammation process. The Eustachian tube has an important role
in maintaining ventilation and protecting the middle ear cavity,
and in the drainage of middle ear fluid (Coticchia 2013). MEE
is also caused by dysfunction of the epithelial sodium channel
(ENaC) in controlling the periciliary fluid that is essential for
maintaining a fluid-freemiddle ear cavity. An in vitro study showed
that interleukin-1β (IL-1β), an important inflammatory cytokine
mostly found in theMEE, inhibits fluid absorption by suppressing
ENaC in various epithelia including airway epithelial cells (Choi
2006; Choi 2007).
Despite the benefits of using antibiotics for some ear infections,
they have several consequences due to bacterial death and the re-
lease of inflammatory bacterial products. Thismay induce andpro-
long inflammation in the middle ear and lead to otitis media with
effusion (OME) and further episodes of AOM (Principi 2013).
This suggests that the inflammatory mechanism may be involved
in the basic pathogenesis of AOM. This mechanism is induced
by both cellular and chemical mediators in the middle ear. These
mediators (i.e. cytokines, chemokines, mast cells, prostaglandins,
leukotrienes) contribute by altering vascular permeability, increas-
ingmucous glycoprotein secretion and stimulating the chemotaxis
process, epithelial secretion activity and other mediators (Juhn
2008).
Based on this pathogenesis, an intervention that suppresses the
inflammatory process could have an important role in the res-
olution of AOM, including inhibition of the interleukin-1 (IL-
1) and tumour necrosis factor-alpha (TNF-α) early-response cy-
tokines that are commonly found in children. Corticosteroids play
an important role in inhibiting the inflammation process through
genomic and non-genomic mechanisms, including inhibition of
mediators that are involved in middle ear inflammatory processes
(Juhn 2008). An animal study showed that AOM inflammatory
disease generally peaks between three and five days and resolves
by 10 to 14 days (MacArthur 2006). However, a randomised con-
trolled trial (RCT) has shown no significant clinical benefits of
the use of corticosteroids for AOM (Chonmaitree 2003). A tem-
porary improvement in tympanometry in patients who received
corticosteroids suggested the possibility that discontinuation after
a five-day course of corticosteroid induced a rebound effect due to
ongoing middle ear inflammation, which indicated the need for a
longer duration of treatment (Chonmaitree 2003).
Corticosteroids have been found to be effective in some ARIs, for
example when combined with antibiotics for patients with sore
throat (Hayward 2012). A recent study has shown that the use
of oral corticosteroids as an additional treatment to antibiotics
for AOMwith discharge through tympanostomy tubes shortened
the duration of otorrhoea (McCormick 2003). However, a few
small trials on the use of corticosteroids as an additional treatment
to antibiotics for AOM in children have reported varied results
(Wang 2007).
As a monotherapy, oral corticosteroids are not effective for adults
with clinically diagnosed acute sinusitis (Venekamp 2014). Never-
theless, when combined with antibiotics, oral corticosteroids may
have a modest beneficial effect (Venekamp 2014). An RCT also
reported no significant difference between oral prednisolone as a
standalone therapy and placebo in hospitalised patients with acute
viral mild-to-moderate wheezing (Panickar 2009). However, as
close observation (without antibiotic administration) is a treat-
ment option for AOM, there is a risk of persistent and recurrent
AOM in some cases, and there is involvement of an inflammatory
mechanism in the middle ear, it is worthwhile identifying the ef-
fects of corticosteroids as a monotherapy for AOM in children.
Why it is important to do this review
The therapeutic options for the management of AOM in chil-
dren are currently unsatisfactory. An effective treatment modality
is needed and systemic corticosteroids may fill that role, either as
a monotherapy or in addition to antibiotics. A recent literature
review concluded that there was insufficient evidence to recom-
mend corticosteroids for AOM (Principi 2013). However, poten-
tially relevant studies were not included in that review and there-
fore there is need for a further systematic assessment (McCormick
2003; Ruohola 1999; Wang 2007). An up to date Cochrane re-
view is warranted to assess the effects of corticosteroids, as another
treatment option, for the treatment of AOM in children.
O B J E C T I V E S
To assess the effects of corticosteroids, with and without antibi-
otics, for AOM in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs).
Types of participants
We will include children aged up to 15 years with AOM. AOM
often correlates with immaturity of the immune system, therefore
we will set the age limit at 15 years because maturation of the B-
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cells involved in the immune system commences at that point and
beyond (McKenna 2001).
AOM is defined as “the rapid onset of ear pain accompanied with
bulging and/or hyperaemic tympanic membrane and the presen-
tation of middle ear effusion” (Lieberthal 2013; Pichichero 2015).
We will include both unilateral and bilateral AOM. Participants
will be included irrespective of the setting from which they were
recruited.
We will exclude children with contraindications to corticosteroid
therapy (e.g. immunodeficient or immunocompromised, or both),
children with anatomic or physiological disorders of the ear or
nasopharynx and those with chronic MEE. We will also exclude
children with ventilation tubes because this procedure is princi-
pally used for non-acute (chronic) otitis media with effusion.
Types of interventions
We will include studies that compare any type of systemic corti-
costeroids (e.g. oral, parenteral) with placebo, either without an-
tibiotics (i.e. corticosteroid versus placebo) or with antibiotics (i.e.
antibiotics plus corticosteroid versus antibiotics plus placebo).
We will exclude studies using any type of topical corticosteroids
(e.g. intranasal).
For symptomatic treatment, patients may have received ac-
etaminophen as an antipyretic and analgesic treatment (Bertin
1996).
Types of outcome measures
Primary outcomes
1. Proportion of children with pain at various time points (24
hours; two to three days; and four to seven days - time points
taken from Venekamp 2015).
2. Reduction of overall or specific symptoms (e.g. ear
discomfort, hearing loss, irritability, sleep disturbance,
diminished appetite). Reduction of overall or specific symptoms
may be measured using visual analogue scales or validated
symptom scales specific to otitis media such as the Acute Otitis
Media Severity of Symptoms Scale (AOM-SOS), Otitis Media
Outcome-22 questionnaire (OMO-22), Otitis Media-6 quality
of life survey (OM-6), or others (Timmerman 2007).
3. Reduction in overall or specific symptom duration.
4. Adverse effects.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points as an objective assessment of the resolution of AOM (e.g.
middle ear pressure, tympanogram curve types).
2. Tympanic membrane perforation.
3. Contralateral otitis (in children with unilateral infection).
4. AOM recurrence, which is defined as the occurrence of
AOM episodes within one month after completion of antibiotic
therapy (Pichichero 2000).
5. Serious complications related to AOM such as mastoiditis
and meningitis.
Search methods for identification of studies
Electronic searches
We will search the following databases from inception to the
present:
1. Cochrane Central Register of Controlled Trials
(CENTRAL);
2. MEDLINE (Ovid);
3. Embase (Elsevier);
4. CINAHL (EBSCO);
5. Web of Science (Thomson Reuters); and
6. LILACS (BIREME).
We will combine the search terms set out in Appendix 1 with
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity and precision-maximis-
ing version (2008 revision) (Lefebvre 2011).Wewill assesswhether
we need to apply a filter for retrieving studies in children (Boluyt
2008). This will depend on the number of search results retrieved.
We will not impose language or publication restrictions.
Searching other resources
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP) (
http://apps.who.int/trialsearch/). We will check the reference lists
of all primary studies and review articles for additional references.
We will contact experts in the field to identify additional unpub-
lished materials.
Data collection and analysis
Selection of studies
Three review authors (RR, YP, EDS) will independently screen
the titles and abstracts of all potential studies identified as a result
of the searches. We will retrieve full-text study reports of poten-
tially relevant studies. Three review authors (RR, YP, EDS) will
independently screen the retrieved reports to identify studies for
inclusion and they will record the reasons for exclusion of ineligi-
ble studies. We will resolve disagreements through discussion or, if
required, consult with a third review author (EMB or CDM). We
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will identify and exclude duplicates and collate multiple reports
of the same study so that each study rather than each report is
assessed in the review. We will record the selection process in suf-
ficient detail to complete a PRISMA flow diagram (Moher 2010).
Data extraction and management
We will use a data collection form, which has been piloted on at
least one study in the review, to collate study characteristics and
outcome data. Three review authors (RR, YP, EDS) will indepen-
dently extract study characteristics from included studies. We will
extract the following study characteristics:
1. methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study;
2. participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, inclusion criteria and exclusion
criteria;
3. interventions: intervention, comparison, concomitant
medications and excluded medications;
4. outcomes: primary and secondary outcomes specified and
collected, and time points reported; and
5. notes: funding for trial and notable conflicts of interest of
trial authors.
Three review authors (RR, YP, EDS) will independently extract
outcome data from the included studies.Wewill note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way. We will resolve disagreements by consen-
sus. A review author (RR) will input data into the Review Man-
ager software (RevMan 2014). We will double-check that data are
entered correctly by comparing the data presented in the system-
atic review with the study reports. Two review authors (YP, EDS)
will spot-check study characteristics for accuracy against the trial
report.
Assessment of risk of bias in included studies
Three review authors (RR, YP, EDS) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion with another re-
view author (EMB or CDM). We will assess the risk of bias ac-
cording to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We will grade each potential source of bias as high, low or unclear
and we will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the risk of bias judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes, where necessary. Where information
on risk of bias relates to unpublished data or correspondence with
a trialist, we will note this in the ’Risk of bias’ table.
We will take into account the risk of bias for the studies that
contribute to that outcome when considering treatment effects.
Measures of treatment effect
We will enter the outcome data for each study into the data tables
in RevMan 2014 to calculate the treatment effects.We will use the
risk ratio (RR)with 95%confidence interval (CI) for dichotomous
outcomes and the mean difference (MD) or standardised mean
difference (SMD) for continuous outcomes.
Wewill undertakemeta-analyses only where this ismeaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
Unit of analysis issues
We do not expect any trials in this area to have applied cross-over
or cluster-randomised designs.
For studies with more than two intervention groups, where more
than two of the groups are eligible for this review, we will follow
the methods in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). That is, in studies with more than
one control group or more than one intervention group, we will
combine the results of the control or intervention groups, respec-
tively.
Dealing with missing data
Wewill contact trial authors to verify key study characteristics and
to obtain missing numerical outcome data where possible (e.g.
when a study is identified as an abstract only). Where this is not
possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such studies in the
overall assessment of results using the ’Risk of bias’ assessment.
If numerical outcome data are missing, such as standard devia-
tions (SDs) or correlation coefficients, and they cannot be ob-
tained from the trial authors, we will calculate the missing param-
eters from other available statistics such as P values according to
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). If values are imputed (e.g.
correlation coefficients), rather than calculated, we will perform
sensitivity analyses to assess how sensitive the results are to reason-
able changes in the assumptions that are made in the imputation.
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Assessment of heterogeneity
Wewill use theChi² test and the I² statistic tomeasure heterogene-
ity among the studies in each analysis. If we identify substantial
heterogeneity (over 50% as explained in the Cochrane Handbook
for Systematic Reviews of Interventions; Higgins 2011), we will re-
port this and explore the possible causes by conducting prespeci-
fied subgroup analysis. Nonetheless, we are aware that there is un-
certainty in the I² statistic measurement when there are few studies
in a meta-analysis. In that case, we will use a P value of 0.10 rather
than 0.05 in the Chi² test to determine statistical heterogeneity
(Higgins 2011).
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small study and publication
biases.
Data synthesis
Wewill pool data from studies that we judge to be clinically homo-
geneous using RevMan 2014, with a fixed-effect model. If a single
true effect is not plausible, due to variation in populations and
interventions or substantial heterogeneity, we will use a random-
effects model instead (DerSimonian and Laird method) (Higgins
2011). If more than one study provides usable data in any sin-
gle comparison, we will perform a meta-analysis. We will analyse
primary outcomes at three time points, namely 24 hours; two to
three days; and four to seven days.
GRADE and ’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
primary outcomes: proportion of children with pain at various
time points (24 hours; two to three days; and four to seven days);
reduction of overall or specific symptoms; reduction in overall or
specific symptom duration; and adverse effects of corticosteroids.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data to the meta-analyses for the pre-
specified outcomes (Atkins 2004; GRADE 2004). We will use
the methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using GRADEproGDT software
(GRADEproGDT 2015). We will justify all decisions to down-
grade or upgrade the quality of studies using footnotes and we will
make comments to aid readers’ understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses if there are
sufficient studies:
1. short- versus long-term use of corticosteroids ( ≤ one week
versus > one week);
2. type of corticosteroids (i.e. prednisolone, dexamethasone,
etc.); and
3. corticosteroids as monotherapy versus adjuvant to
antibiotics.
Wewill use theChi² test to test for subgroup interactions inReview
Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out sensitivity analyses by identifying and ex-
cluding studies with high risk of bias or low methodological qual-
ity based on the Cochrane ’Risk of bias’ assessment, if there are
sufficient included studies to make this feasible.
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
MEDLINE (Ovid)
1 exp Otitis Media/ (22799)
2 otitis media.tw. (17913)
3 (middle ear adj5 (infect* or inflam*)).tw. (1878)
4 (ome or aom).tw. (7702)
5 or/1-4 (33474)
6 exp Adrenal Cortex Hormones/ (355953)
7 adrenal cortex hormone*.tw,nm. (56917)
8 corticosteroid*.tw,nm. (83470)
9 corticoid*.tw,nm. (5657)
10 steroid*.tw,nm. (284604)
11 glucocorticoid*.tw,nm. (92417)
12 exp Pregnenediones/ (173193)
13 pregnenedione*.tw,nm. (2108)
14 pregnenolone*.tw,nm. (6726)
15 hydrocortisone.tw,nm. (70460)
16 hydroxypregnenolone.tw,nm. (928)
17 tetrahydrocortisol.tw,nm. (471)
18 cortodoxone.tw,nm. (779)
19 cortisone.tw,nm. (22609)
20 corticosterone.tw,nm. (30378)
21 triamcinolone.tw,nm. (10351)
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22 prednisone.tw,nm. (47956)
23 prednisolone.tw,nm. (41014)
24 paramethasone.tw,nm. (246)
25 methylprednisolone.tw,nm. (22772)
26 dexamethasone.tw,nm. (62108)
27 clobetasol.tw,nm. (1395)
28 beclomethasone.tw,nm. (3662)
29 betamethasone.tw,nm. (6960)
30 budesonide.tw,nm. (5108)
31 (efcortesol or hydrocortone or solu-cortef ).tw,nm. (35)
32 (betnelan or betnesol).tw,nm. (25)
33 (deflazacort or calcort).tw,nm. (486)
34 (medrone or solu-medrone or depo-medrone).tw,nm. (17)
35 kenalog.tw,nm. (185)
36 (novolizer or pulmicort or symbicort).tw,nm. (328)
37 (beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte).tw,nm. (287)
38 cortisol.tw,nm. (51031)
39 or/6-38 (712225)
40 5 and 39 (1017)
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